Pharma Reviews: BRIEF-Shenzhen Hepalink Pharmaceutical issues 2016 public corporate bonds ...

... (DoJ) into suspected price collusion in the pharmaceutical industry is unlikely to have a significant impact on Indian pharma firms, says Fitch Ratings ...
Read more: BRIEF-Shenzhen Hepalink Pharmaceutical issues 2016 public corporate bonds ...